Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Transition Therapeutics Inc (NASDAQ:TTHI)

2.16
Delayed Data
As of 12:00pm ET
 -0.0132 / -0.61%
Today’s Change
1.95
Today|||52-Week Range
9.30
-68.41%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$84.4M

Company Description

Transition Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapeutics for disease indications with large markets. It operates through research and development of therapeutic agents segment. The company's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada.

Contact Information

Transition Therapeutics, Inc.
101 College Street
Toronto Ontario M5G 1L7
P:(416) 260-7770
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Tony F. CruzChairman & Chief Executive Officer
Carl DamianiPresident & Chief Operating Officer
Nicole Rusaw-GeorgeChief Financial Officer
Aleksandra PastrakVP-Clinical Development & Medical Officer
Bruce P. ConnopVP-Non Clinical & Pharmaceutical Development